Tags

Type your tag names separated by a space and hit enter

Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey.
PLoS One. 2020; 15(9):e0238614.Plos

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with severe respiratory illness emerged in Wuhan, China, in late 2019. The virus has been able to spread promptly across all continents in the world. The current pandemic has posed a great threat to public health concern and safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from the nasopharyngeal sample of a patient in Turkey with confirmed COVID-19. We determined that the Vero E6 and MA-104 cell lines are suitable for supporting SARS-CoV-2 that supports viral replication, development of cytopathic effect (CPE) and subsequent cell death. Phylogenetic analyses of the whole genome sequences showed that the hCoV-19/Turkey/ERAGEM-001/2020 strain clustered with the strains primarily from Australia, Canada, England, Iran and Kuwait and that the cases in the nearby clusters were reported to have travel history to Iran and to share the common unique nucleotide substitutions.

Authors+Show Affiliations

Department of Microbiology, Medical Faculty, Erciyes University, Kayseri, Turkey. Vaccine Research, Development and Application Center, Erciyes University, Kayseri, Turkey.Department of Microbiology, Medical Faculty, Erciyes University, Kayseri, Turkey. Vaccine Research, Development and Application Center, Erciyes University, Kayseri, Turkey.Department of Microbiology, Medical Faculty, Erciyes University, Kayseri, Turkey. Vaccine Research, Development and Application Center, Erciyes University, Kayseri, Turkey.Gen Era Diagnostics Inc. Barbaros, Istanbul, Turkey.Vaccine Research, Development and Application Center, Erciyes University, Kayseri, Turkey.Department of Microbiology and Infectious Disease, Kayseri City Training and Research Hospital, Kayseri, Turkey.Department of Microbiology and Infectious Disease, Kayseri City Training and Research Hospital, Kayseri, Turkey.Gen Era Diagnostics Inc. Barbaros, Istanbul, Turkey.Department of Microbiology, Medical Faculty, Erciyes University, Kayseri, Turkey. Vaccine Research, Development and Application Center, Erciyes University, Kayseri, Turkey.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32936826

Citation

Pavel, Shaikh Terkis Islam, et al. "Isolation and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 in Turkey." PloS One, vol. 15, no. 9, 2020, pp. e0238614.
Pavel STI, Yetiskin H, Aydin G, et al. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PLoS One. 2020;15(9):e0238614.
Pavel, S. T. I., Yetiskin, H., Aydin, G., Holyavkin, C., Uygut, M. A., Dursun, Z. B., Celik, İ., Cevik, C., & Ozdarendeli, A. (2020). Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PloS One, 15(9), e0238614. https://doi.org/10.1371/journal.pone.0238614
Pavel STI, et al. Isolation and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 in Turkey. PLoS One. 2020;15(9):e0238614. PubMed PMID: 32936826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. AU - Pavel,Shaikh Terkis Islam, AU - Yetiskin,Hazel, AU - Aydin,Gunsu, AU - Holyavkin,Can, AU - Uygut,Muhammet Ali, AU - Dursun,Zehra Bestepe, AU - Celik,İlhami, AU - Cevik,Ceren, AU - Ozdarendeli,Aykut, Y1 - 2020/09/16/ PY - 2020/05/05/received PY - 2020/08/20/accepted PY - 2020/9/16/entrez PY - 2020/9/17/pubmed PY - 2020/9/26/medline SP - e0238614 EP - e0238614 JF - PloS one JO - PLoS One VL - 15 IS - 9 N2 - Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with severe respiratory illness emerged in Wuhan, China, in late 2019. The virus has been able to spread promptly across all continents in the world. The current pandemic has posed a great threat to public health concern and safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from the nasopharyngeal sample of a patient in Turkey with confirmed COVID-19. We determined that the Vero E6 and MA-104 cell lines are suitable for supporting SARS-CoV-2 that supports viral replication, development of cytopathic effect (CPE) and subsequent cell death. Phylogenetic analyses of the whole genome sequences showed that the hCoV-19/Turkey/ERAGEM-001/2020 strain clustered with the strains primarily from Australia, Canada, England, Iran and Kuwait and that the cases in the nearby clusters were reported to have travel history to Iran and to share the common unique nucleotide substitutions. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/32936826/Isolation_and_characterization_of_severe_acute_respiratory_syndrome_coronavirus_2_in_Turkey_ L2 - https://dx.plos.org/10.1371/journal.pone.0238614 DB - PRIME DP - Unbound Medicine ER -